Reduced induction of human β-defensins is involved in the pathological mechanism of cutaneous adverse effects caused by epidermal growth factor receptor monoclonal antibodies.
Aged
Aged, 80 and over
Anti-Infective Agents
/ analysis
Antibodies, Monoclonal
/ adverse effects
Drug Eruptions
/ etiology
Drug-Related Side Effects and Adverse Reactions
/ pathology
Epidermis
/ drug effects
ErbB Receptors
/ antagonists & inhibitors
Female
Humans
Immunity, Innate
/ drug effects
Male
Middle Aged
Staphylococcal Skin Infections
/ chemically induced
beta-Defensins
/ analysis
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
accepted:
21
05
2020
pubmed:
28
5
2020
medline:
29
7
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
Epidermal growth factor receptor inhibitors (EGFRIs) frequently cause cutaneous adverse effects such as papulopustular eruptions. However, the mechanism of the reactions remains unclear. To assess the pathological mechanism of cutaneous adverse reactions caused by EGFRIs, we investigated whether EGFRIs have an influence on the innate immune response of the skin. Levels of human β-defensins (hBDs), which serve as the first line of defence against infection by pathogenic microorganisms, in the stratum corneum samples of patients treated with EGFR. monoclonal antibodies were measured before and after starting therapy. There were no obvious trends in hBD production in patients without eruptions, whereas a significant decrease in hBD1 and hBD3 production and a nonsignficant decrease in hBD2 production were observed in patients who developed papulopustular eruptions. Our results suggest that a reduction in hBD contributes to the increased incidence of papulopustular eruptions.
Substances chimiques
Anti-Infective Agents
0
Antibodies, Monoclonal
0
beta-Defensins
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1055-1058Subventions
Organisme : Japan Agency for Medical Research and Development (AMED)
Organisme : JSPS KAKENHI
ID : JP18K16037
Informations de copyright
© 2020 British Association of Dermatologists.
Références
Macdonald JB, Macdonald B, Golitz LE et al. Cutaneous adverse effects of targeted therapies: Part I: inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203-18.
Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
Prasad SV, Fiedoruk K, Daniluk T et al. Expression and function of host defense peptides at inflammation sites. Int J Mol Sci 2020; 21: 104.
Ommori R, Park K, Miyagawa F et al. EGFR inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response. Br J Dermatol 2018; 178: 796-7.
Park K, Ommori R, Imoto K, Asada H. Epidermal growth factor receptor inhibitors selectively inhibit the expression of human β-defensins induced by Staphylococcus epidermidis. J Dermatol Sci 2014; 75: 94-9.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2012; 48: 452-8.
Ommori R, Ouji N, Mizuno F et al. Selective induction of antimicrobial peptides from keratinocytes by staphylococcal bacteria. Microb Pathog 2013; 56: 35-9.
Eilers RE Jr, Gandhi M, Patel JD et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.
Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer 2016; 24: 3943-50.